<DOC>
	<DOCNO>NCT01723150</DOCNO>
	<brief_summary>Background : Klebsiella pneumoniae liver abscess common etiology liver abscess Singapore much Asia , incidence increase . Current management include prolonged intravenous antibiotic therapy , limited evidence guide oral conversion . The implicated K1/K2 capsule strain Klebsiella pneumoniae almost universally susceptible ciprofloxacin , antibiotic high oral bioavailability . Our primary aim compare efficacy early ( &lt; 1 week ) step-down oral antibiotic , continue 4 week intravenous antibiotic , patient Klebsiella liver abscess . Methods/Design : The study design multi-centre randomised open-label active comparator-controlled non-inferiority trial , non-inferiority margin 12 % . Eligible participant inpatient age 21 CT ultrasound scan suggestive liver abscess , Klebsiella pneumoniae isolate abscess fluid blood . Randomisation intervention active control arm perform 1:1 allocation ratio . Participants randomise active control arm receive IV ceftriaxone 2 gram daily complete total 4 week IV antibiotic . Participants randomise intervention arm immediately convert oral ciprofloxacin 750mg twice daily . At week 4 , participant abdominal imaging assess clinical response ( CRP &lt; 20 mg/l , absence fever , plus scan showing maximal diameter abscess reduce ) . If criterion meet , antibiotic stop ; , oral antibiotic continue , reassessment clinical response fortnightly . If criteria clinical response meet week 12 , primary endpoint clinical cure meet . A cost analysis perform assess cost save early conversion oral antibiotic , quality-of-life analysis perform assess treatment oral antibiotic less burdensome prolonged IV antibiotic . Discussion : Our result would help inform local international practice guideline regard optimal antibiotic management Klebsiella liver abscess . A finding non-inferiority may translate wide adoption cost-effective strategy reduces hospital length stay improve patient-centered outcome satisfaction .</brief_summary>
	<brief_title>Antibiotics Klebsiella Liver Abscess Study</brief_title>
	<detailed_description />
	<mesh_term>Abscess</mesh_term>
	<mesh_term>Klebsiella Infections</mesh_term>
	<mesh_term>Liver Abscess</mesh_term>
	<mesh_term>Liver Abscess , Pyogenic</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Ceftriaxone</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<criteria>Inclusion Criteria 1 . Inpatient time enrollment 2 . Age &gt; = 21 year 3 . Computed tomography ( CT ) ultrasound ( US ) within precede 7 day suggestive liver abscess , define presence one focal area hypo hyperattenuation within liver 4 . Klebsiella pneumoniae isolate abscess fluid blood collect within precede 7 day 5 . Able willing give inform consent Exclusion Criteria All subject meet follow exclusion criterion baseline exclude participation : 1 ) Polymicrobial abscess additional organism isolate blood abscess fluid within precede 7 day 2a ) Klebsiella pneumoniae resistant Ceftriaxone AND Ertapenem 2b ) Klebsiella pneumoniae resistant Ciprofloxacin AND Cotrimoxazole 3 ) On effective* IV antibiotic &gt; 7 day 4a ) Hypersensitivity cephalosporin AND carbapenems ; define history rash , urticaria , angiodema , bronchospasm circulatory collapse follow prior administration . 4b ) Hypersensitivity fluoroquinolones AND sulpha drug ; define history rash , urticaria , angioedema , bronchospasm circulatory collapse follow prior administration . 4c ) History penicillin anaphylaxis ( angioedema , bronchospasm circulatory collapse ) . Subjects history rash urticaria unknown reaction penicillin include . 5 ) Inability take oral medication reason 6 ) Severe sepsis septic shock define unresolved hypotension ( MAP &lt; 70 ) tachycardia ( HR &gt; 110 ) , requirement inotropic support ventilation time eligibility . Should subject 's hypotension tachycardia subsequently resolve , cease require inotropes ventilation within 7 day , may reconsider eligibility . 7 ) Established endophthalmitis time screen ( patient visual symptom ophthalmology review prior enrollment ) 8 ) Established central nervous system abscess time screening ( patient focal neurology CT head prior enrollment ) 9 ) Women pregnant breastfeed 10 ) Inability obtain consent subject 11 ) Patients tizanidine theophylline 12 ) Patients concomitant drug result prolongation QT interval ( e.g. , class IA class III antiarrhythmic ) risk factor torsade de pointes ( e.g. , know QT prolongation , uncorrected hypokalemia ) 13 ) Patients whose K. pneumoniae test resistant ciprofloxacin , contraindication ciprofloxacin test G6PD deficiency , exclude deficient 14 ) Severe immunocompromise ( e.g. , active leukemia lymphoma , generalized malignancy , aplastic anemia , solid organ transplant , bone marrow transplant within 2 year transplantation , transplant long duration still immunosuppressive drug graftversushost disease , congenital immunodeficiency , current radiation therapy , HIV/AIDS CD4 lymphocyte count &lt; 200 patient immunosuppressant medication ) 15 ) Creatinine clearance &lt; 15 ml/min *defined antibiotic Klebsiella pneumoniae isolate blood abscess fluid susceptible</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Klebsiella pneumoniae</keyword>
</DOC>